Glibenclamide for the Treatment of Ischemic and Hemorrhagic Stroke
Abstract
:1. Introduction
2. Mechanisms of Sulfonylurea Receptor 1 (Sur1) Pathology
3. Glibenclamide Uptake in Central Nervous System (CNS) Hemorrhage and Ischemia
4. Ischemic Stroke
4.1. Targeting Sur1 in CNS Ischemia—Animal Models
4.2. Glibenclamide Inhibition of Sur1 in Non-Lethal Stroke
4.3. Glibenclamide Inhibition of Sur1 in Lethal Stroke
4.4. Glibenclamide vs. Recombinant Tissue Plasminogen Activator (rtPA)
4.5. Retrospective Clinical Studies
4.6. Prospective Clinical Studies
5. Sur1 in Hemorrhagic Stroke
5.1. Subarachnoid Hemorrhage
5.2. Targeting Sur1 in Subarachnoid Hemorrhage
6. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Berrouschot, J.; Sterker, M.; Bettin, S.; Koster, J.; Schneider, D. Mortality of space-occupying (“malignant”) middle cerebral artery infarction under conservative intensive care. Intensive Care Med. 1998, 24, 620–623. [Google Scholar] [CrossRef] [PubMed]
- Hacke, W.; Schwab, S.; Horn, M.; Spranger, M.; de Georgia, M.; von Kummer, R. “Malignant” middle cerebral artery territory infarction: Clinical course and prognostic signs. Arch. Neurol. 1996, 53, 309–315. [Google Scholar] [CrossRef] [PubMed]
- Kleindorfer, D.; Lindsell, C.J.; Brass, L.; Koroshetz, W.; Broderick, J.P. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008, 39, 924–928. [Google Scholar] [CrossRef] [PubMed]
- Jauss, M.; Schutz, H.J.; Tanislav, C.; Misselwitz, B.; Rosenow, F. Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy. Eur. J. Neurol. 2010, 17, 555–561. [Google Scholar] [CrossRef] [PubMed]
- Adeoye, O.; Hornung, R.; Khatri, P.; Kleindorfer, D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: A doubling of treatment rates over the course of 5 years. Stroke 2011, 42, 1952–1955. [Google Scholar] [CrossRef] [PubMed]
- Singer, O.C.; Hamann, G.F.; Misselwitz, B.; Steinmetz, H.; Foerch, C. Time trends in systemic thrombolysis in a large hospital-based stroke registry. Cerebrovasc. Dis. 2012, 33, 316–321. [Google Scholar] [CrossRef] [PubMed]
- Sacco, S.; Marini, C.; Toni, D.; Olivieri, L.; Carolei, A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009, 40, 394–399. [Google Scholar] [CrossRef] [PubMed]
- Tosun, C.; Kurland, D.B.; Mehta, R.; Castellani, R.J.; de Jong, J.L.; Kwon, M.S.; Woo, S.K.; Gerzanich, V.; Simard, J.M. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke 2013, 44, 3522–3528. [Google Scholar] [CrossRef] [PubMed]
- Marble, A. Glibenclamide, a new sulphonylurea: Whither oral hypoglycaemic agents? Drugs 1971, 1, 109–115. [Google Scholar] [CrossRef] [PubMed]
- Feldman, J.M. Glyburide: A second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 1985, 5, 43–62. [Google Scholar] [PubMed]
- Kramer, W.; Muller, G.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Hartz, D.; Summ, H.D. The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels. Diabetes Res. Clin. Pract. 1995, 28, S67–S80. [Google Scholar] [CrossRef] [PubMed]
- Ashcroft, F.M. Mechanisms of the glycaemic effects of sulfonylureas. Horm. Metab. Res. 1996, 28, 456–463. [Google Scholar] [CrossRef] [PubMed]
- Panten, U.; Schwanstecher, M.; Schwanstecher, C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp. Clin. Endocrinol. Diabetes 1996, 104, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Foster, P.D.; Mamdani, M.M.; Juurlink, D.N.; Shah, B.R.; Paterson, J.M.; Gomes, T. Trends in selection and timing of first-line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006. Diabet. Med. 2013, 30, 1209–1213. [Google Scholar] [CrossRef] [PubMed]
- Woo, S.K.; Kwon, M.S.; Ivanov, A.; Gerzanich, V.; Simard, J.M. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. J. Biol. Chem. 2013, 288, 3655–3667. [Google Scholar] [CrossRef] [PubMed]
- Ortega, F.J.; Gimeno-Bayon, J.; Espinosa-Parrilla, J.F.; Carrasco, J.L.; Batlle, M.; Pugliese, M.; Mahy, N.; Rodriguez, M.J. ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats. Exp. Neurol. 2012, 235, 282–296. [Google Scholar] [CrossRef] [PubMed]
- Ortega, F.J.; Jolkkonen, J.; Mahy, N.; Rodriguez, M.J. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2013, 33, 356–364. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Chen, M.; Tarasov, K.V.; Bhatta, S.; Ivanova, S.; Melnitchenko, L.; Tsymbalyuk, N.; West, G.A.; Gerzanich, V. Newly expressed SUR1-regulated NC (Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat. Med. 2006, 12, 433–440. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Yurovsky, V.; Tsymbalyuk, N.; Melnichenko, L.; Ivanova, S.; Gerzanich, V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009, 40, 604–609. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Tsymbalyuk, N.; Tsymbalyuk, O.; Ivanova, S.; Yurovsky, V.; Gerzanich, V. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke 2010, 41, 531–537. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Geng, Z.; Silver, F.L.; Sheth, K.N.; Kimberly, W.T.; Stern, B.J.; Colucci, M.; Gerzanich, V. Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann. N. Y. Acad. Sci. 2012, 1268, 95–107. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Woo, S.K.; Tsymbalyuk, N.; Voloshyn, O.; Yurovsky, V.; Ivanova, S.; Lee, R.; Gerzanich, V. Glibenclamide-10-h treatment window in a clinically relevant model of stroke. Transl. Stroke Res. 2012, 3, 286–295. [Google Scholar] [CrossRef] [PubMed]
- Wali, B.; Ishrat, T.; Atif, F.; Hua, F.; Stein, D.G.; Sayeed, I. Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. Stroke Res. Treat. 2012, 2012, 460909. [Google Scholar] [PubMed]
- Tan, F.; Li, H.; Ma, M.; Yu, Y. Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats. Brain Res. 2014, 1560, 83–90. [Google Scholar] [CrossRef] [PubMed]
- Kunte, H.; Schmidt, S.; Eliasziw, M.; del Zoppo, G.J.; Simard, J.M.; Masuhr, F.; Weih, M.; Dirnagl, U. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007, 38, 2526–2530. [Google Scholar] [CrossRef] [PubMed]
- Kunte, H.; Busch, M.A.; Trostdorf, K.; Vollnberg, B.; Harms, L.; Mehta, R.I.; Castellani, R.J.; Mandava, P.; Kent, T.A.; Simard, J.M. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann. Neurol. 2012, 72, 799–806. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Sheth, K.N.; Kimberly, W.T.; Stern, B.J.; del Zoppo, G.J.; Jacobson, S.; Gerzanich, V. Glibenclamide in cerebral ischemia and stroke. Neurocrit. Care 2014, 20, 319–333. [Google Scholar] [CrossRef] [PubMed]
- Sheth, K.N.; Kimberly, W.T.; Elm, J.J.; Kent, T.A.; Mandava, P.; Yoo, A.J.; Thomalla, G.; Campbell, B.; Donnan, G.A.; Davis, S.M.; et al. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke 2014, 45, 281–283. [Google Scholar] [CrossRef] [PubMed]
- Kimberly, W.T.; Battey, T.W.; Pham, L.; Wu, O.; Yoo, A.J.; Furie, K.L.; Singhal, A.B.; Elm, J.J.; Stern, B.J.; Sheth, K.N. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit. Care 2014, 20, 193–201. [Google Scholar] [CrossRef] [PubMed]
- Sheth, K.N.; Kimberly, W.T.; Elm, J.J.; Kent, T.A.; Yoo, A.J.; Thomalla, G.; Campbell, B.; Donnan, G.A.; Davis, S.M.; Albers, G.W.; et al. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit. Care 2014, 21, 43–51. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Geng, Z.; Woo, S.K.; Ivanova, S.; Tosun, C.; Melnichenko, L.; Gerzanich, V. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 2009, 29, 317–330. [Google Scholar] [CrossRef] [PubMed]
- Tosun, C.; Koltz, M.T.; Kurland, D.B.; Ijaz, H.; Gurakar, M.; Schwartzbauer, G.; Coksaygan, T.; Ivanova, S.; Gerzanich, V.; Simard, J.M. The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity. Brain Sci. 2013, 3, 215–238. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Woo, S.K.; Schwartzbauer, G.T.; Gerzanich, V. Sulfonylurea receptor 1 in central nervous system injury: A focused review. J. Cereb. Blood Flow Metab. 2012, 32, 1699–1717. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Woo, S.K.; Gerzanich, V. Transient receptor potential melastatin 4 and cell death. Pflugers Arch. 2012, 464, 573–582. [Google Scholar] [CrossRef] [PubMed]
- Thomzig, A.; Laube, G.; Pruss, H.; Veh, R.W. Pore-forming subunits of K-ATP channels, Kir6.1 and Kir6.2, display prominent differences in regional and cellular distribution in the rat brain. J. Comp. Neurol. 2005, 484, 313–330. [Google Scholar] [CrossRef] [PubMed]
- Yamada, K.; Inagaki, N. Neuroprotection by KATP channels. J. Mol. Cell Cardiol. 2005, 38, 945–949. [Google Scholar] [CrossRef] [PubMed]
- Sun, H.S.; Feng, Z.P. Neuroprotective role of ATP-sensitive potassium channels in cerebral ischemia. Acta Pharmacol. Sin. 2013, 34, 24–32. [Google Scholar] [CrossRef] [PubMed]
- Bryan, J.; Munoz, A.; Zhang, X.; Dufer, M.; Drews, G.; Krippeit-Drews, P.; Aguilar-Bryan, L. ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007, 453, 703–718. [Google Scholar] [CrossRef] [PubMed]
- Burke, M.A.; Mutharasan, R.K.; Ardehali, H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ. Res. 2008, 102, 164–176. [Google Scholar] [CrossRef] [PubMed]
- Aittoniemi, J.; Fotinou, C.; Craig, T.J.; de, W.H.; Proks, P.; Ashcroft, F.M. Review. SUR1: A unique ATP-binding cassette protein that functions as an ion channel regulator. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2009, 364, 257–267. [Google Scholar] [CrossRef] [PubMed]
- Nistico, R.; Piccirilli, S.; Sebastianelli, L.; Nistico, G.; Bernardi, G.; Mercuri, N.B. The blockade of K+-ATP channels has neuroprotective effects in an in vitro model of brain ischemia. Int. Rev. Neurobiol. 2007, 82, 383–395. [Google Scholar] [PubMed]
- Mehta, R.I.; Ivanova, S.; Tosun, C.; Castellani, R.J.; Gerzanich, V.; Simard, J.M. Sulfonylurea receptor 1 expression in human cerebral infarcts. J. Neuropathol. Exp. Neurol. 2013, 72, 871–883. [Google Scholar] [CrossRef] [PubMed]
- Arundine, M.; Tymianski, M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003, 34, 325–337. [Google Scholar] [CrossRef] [PubMed]
- Bano, D.; Nicotera, P. Ca2+ signals and neuronal death in brain ischemia. Stroke 2007, 38, 674–676. [Google Scholar] [CrossRef] [PubMed]
- Gerzanich, V.; Woo, S.K.; Vennekens, R.; Tsymbalyuk, O.; Ivanova, S.; Ivanov, A.; Geng, Z.; Chen, Z.; Nilius, B.; Flockerzi, V.; et al. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nat. Med. 2009, 15, 185–191. [Google Scholar] [CrossRef] [PubMed]
- Woo, S.K.; Kwon, M.S.; Geng, Z.; Chen, Z.; Ivanov, A.; Bhatta, S.; Gerzanich, V.; Simard, J.M. Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of Abcc8. J. Cereb. Blood Flow Metab. 2012, 32, 525–536. [Google Scholar] [CrossRef] [PubMed]
- Tomiyama, Y.; Brian, J.E., Jr.; Todd, M.M. Cerebral blood flow during hemodilution and hypoxia in rats: Role of ATP-sensitive potassium channels. Stroke 1999, 30, 1942–1947. [Google Scholar] [CrossRef] [PubMed]
- Nedergaard, M.; Kraig, R.P.; Tanabe, J.; Pulsinelli, W.A. Dynamics of interstitial and intracellular pH in evolving brain infarct. Am. J. Physiol. 1991, 260, R581–R588. [Google Scholar] [PubMed]
- Simard, J.M.; Kent, T.A.; Chen, M.; Tarasov, K.V.; Gerzanich, V. Brain oedema in focal ischaemia: Molecular pathophysiology and theoretical implications. Lancet Neurol. 2007, 6, 258–268. [Google Scholar] [CrossRef] [PubMed]
- Ortega, F.J.; Jolkkonen, J.; Rodriguez, M.J. Microglia is an active player in how glibenclamide improves stroke outcome. J. Cereb. Blood Flow Metab. 2013, 33, 1138–1139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walcott, B.P.; Kuklina, E.V.; Nahed, B.V.; George, M.G.; Kahle, K.T.; Simard, J.M.; Asaad, W.F.; Coumans, J.V. Craniectomy for malignant cerebral infarction: Prevalence and outcomes in US hospitals. PLoS One 2011, 6, e29193. [Google Scholar] [CrossRef] [PubMed]
- Lansberg, M.G.; Thijs, V.N.; Bammer, R.; Kemp, S.; Wijman, C.A.; Marks, M.P.; Albers, G.W. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007, 38, 2275–2278. [Google Scholar] [CrossRef] [PubMed]
- Weih, M.; Amberger, N.; Wegener, S.; Dirnagl, U.; Reuter, T.; Einhaupl, K. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 2001, 32, 2029–2032. [Google Scholar] [CrossRef] [PubMed]
- Favilla, C.G.; Mullen, M.T.; Ali, M.; Higgins, P.; Kasner, S.E. Sulfonylurea use before stroke does not influence outcome. Stroke 2011, 42, 710–715. [Google Scholar] [CrossRef] [PubMed]
- Vahedi, K.; Hofmeijer, J.; Juettler, E.; Vicaut, E.; George, B.; Algra, A.; Amelink, G.J.; Schmiedeck, P.; Schwab, S.; Rothwell, P.M.; et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: A pooled analysis of three randomised controlled trials. Lancet Neurol. 2007, 6, 215–222. [Google Scholar] [CrossRef] [PubMed]
- Macdonald, R.L.; Pluta, R.M.; Zhang, J.H. Cerebral vasospasm after subarachnoid hemorrhage: The emerging revolution. Nat. Clin. Pract. Neurol. 2007, 3, 256–263. [Google Scholar] [CrossRef] [PubMed]
- Sehba, F.A.; Pluta, R.M.; Zhang, J.H. Metamorphosis of subarachnoid hemorrhage research: From delayed vasospasm to early brain injury. Mol. Neurobiol. 2011, 43, 27–40. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Schreibman, D.; Aldrich, E.F.; Stallmeyer, B.; Le, B.; James, R.F.; Beaty, N. Unfractionated heparin: Multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage. Neurocrit. Care 2010, 13, 439–449. [Google Scholar] [CrossRef] [PubMed]
- Macdonald, R.L.; Kassell, N.F.; Mayer, S.; Ruefenacht, D.; Schmiedek, P.; Weidauer, S.; Frey, A.; Roux, S.; Pasqualin, A. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008, 39, 3015–3021. [Google Scholar] [CrossRef] [PubMed]
- Stanimirovic, D.; Satoh, K. Inflammatory mediators of cerebral endothelium: A role in ischemic brain inflammation. Brain Pathol. 2000, 10, 113–126. [Google Scholar] [CrossRef] [PubMed]
- Petty, M.A.; Lo, E.H. Junctional complexes of the blood-brain barrier: Permeability changes in neuroinflammation. Prog. Neurobiol. 2002, 68, 311–323. [Google Scholar] [CrossRef] [PubMed]
- Xavier, G.F.; Costa, V.C. Dentate gyrus and spatial behaviour. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 762–773. [Google Scholar] [CrossRef] [PubMed]
- Simard, J.M.; Tosun, C.; Ivanova, S.; Kurland, D.B.; Hong, C.; Radecki, L.; Gisriel, C.; Mehta, R.; Schreibman, D.; Gerzanich, V. Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage. Transl. Stroke Res. 2012, 3, 155–165. [Google Scholar] [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Caffes, N.; Kurland, D.B.; Gerzanich, V.; Simard, J.M. Glibenclamide for the Treatment of Ischemic and Hemorrhagic Stroke. Int. J. Mol. Sci. 2015, 16, 4973-4984. https://doi.org/10.3390/ijms16034973
Caffes N, Kurland DB, Gerzanich V, Simard JM. Glibenclamide for the Treatment of Ischemic and Hemorrhagic Stroke. International Journal of Molecular Sciences. 2015; 16(3):4973-4984. https://doi.org/10.3390/ijms16034973
Chicago/Turabian StyleCaffes, Nicholas, David B. Kurland, Volodymyr Gerzanich, and J. Marc Simard. 2015. "Glibenclamide for the Treatment of Ischemic and Hemorrhagic Stroke" International Journal of Molecular Sciences 16, no. 3: 4973-4984. https://doi.org/10.3390/ijms16034973